Plus   Neg

Stock Alert: Hepion Pharma Jumps 35%

Shares of Hepion Pharmaceuticals, Inc. (HEPA) are rising over 35% on Tuesday morning. The biopharmaceutical company announced that its anti-fibrotic drug candidate was efficacious in two pre-clinical research related to COVID-19.

HEPA is currently trading at $3.93, up $1.05 or 36.4583%, on the Nasdaq.

Hepion, a pharma company focusing on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis, said its clinical phase, anti-fibrotic drug candidate, CRV431, was efficacious in two distinct preclinical research models related to COVID-19 disease.

Firstly, CRV431 demonstrated strong anti-inflammatory actions in a non-viral, acute lung injury model and on some measures outperformed dexamethasone, a recently recommended treatment for COVID-19.

Secondly, cell culture experiments demonstrated CRV431 antiviral activity towards SARS-CoV-2, the virus responsible for COVID-19 disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The media mogul and Billionaire Sumner Redstone passed away on Tuesday at the age of 97, his family's holding company National Amusements said in a statement on Wednesday. He was Chairman Emeritus of ViacomCBS and chief executive officer of National Amusements. Customers in the U.S. are preferring digital or touchless payment methods due to concerns arising from the COVID-19 pandemic, a survey said. According to the survey by Rapyd Financial Network, the coronavirus pandemic has raised health and safety concerns around using cash and coins, and is accelerating the pre-existing trend toward digital transactions. American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until December 31, 2020 in response to lower travel demand due to the coronavirus pandemic. This means that the travelers need not pay penalties for changing the origin and destination cities.
Follow RTT